Total Payments
$2,369
2024 Payments
$107.86
Companies
19
Transactions
119
Medicare Patients
3,334
Medicare Billing
$198,620
Payment Breakdown by Category
Food & Beverage$2,108 (89.0%)
Education$261.46 (11.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,108 | 115 | 89.0% |
| Education | $261.46 | 4 | 11.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $760.72 | 38 | $0 (2024) |
| Astellas Pharma US Inc | $359.41 | 13 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $300.79 | 14 | $0 (2022) |
| GlaxoSmithKline, LLC. | $199.32 | 10 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $191.29 | 12 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $175.34 | 14 | $0 (2022) |
| Lilly USA, LLC | $103.09 | 6 | $0 (2023) |
| Cerapedics, Inc. | $94.16 | 1 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $22.80 | 1 | $0 (2021) |
| Amgen Inc. | $21.13 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $107.86 | 5 | GlaxoSmithKline, LLC. ($64.57) |
| 2023 | $422.02 | 18 | Novo Nordisk Inc ($110.28) |
| 2022 | $400.72 | 21 | Novo Nordisk Inc ($279.27) |
| 2021 | $323.40 | 17 | Novo Nordisk Inc ($253.39) |
| 2020 | $82.95 | 5 | Novo Nordisk Inc ($31.69) |
| 2019 | $247.65 | 12 | Astellas Pharma US Inc ($107.98) |
| 2018 | $364.51 | 25 | Janssen Pharmaceuticals, Inc ($123.50) |
| 2017 | $420.29 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($123.76) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 2 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/13/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: DIABETES | ||||||
| 10/06/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Diabetes | ||||||
| 09/07/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: Diabetes | ||||||
| 08/18/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Diabetes | ||||||
| 08/16/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/09/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: Diabetes | ||||||
| 08/08/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: RESPIRATORY | ||||||
| 07/15/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Diabetes | ||||||
| 06/23/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Diabetes | ||||||
| 05/19/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Diabetes | ||||||
| 05/17/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Diabetes | ||||||
| 04/28/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/01/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Diabetes | ||||||
| 03/01/2022 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 02/25/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: Diabetes | ||||||
| 02/17/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.54 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/31/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Cardio-renal | ||||||
| 01/20/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 01/06/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Diabetes | ||||||
| 12/02/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: Diabetes | ||||||
| 11/03/2021 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: Diabetes | ||||||
| 10/20/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Diabetes | ||||||
| 09/13/2021 | Sunovion Pharmaceuticals Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: UROLOGY | ||||||
| 09/09/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Diabetes | ||||||
| 08/26/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 501 | 792 | $121,599 | $37,551 |
| 2022 | 17 | 784 | 1,314 | $167,995 | $52,863 |
| 2021 | 20 | 1,056 | 1,581 | $174,833 | $57,715 |
| 2020 | 16 | 993 | 1,419 | $155,218 | $50,490 |
Total Patients
3,334
Total Services
5,106
Medicare Billing
$198,620
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 133 | 187 | $63,139 | $19,164 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 77 | $19,481 | $5,393 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 85 | $14,450 | $4,606 | 31.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 27 | 27 | $5,805 | $3,329 | 57.3% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 11 | 18 | $3,237 | $1,314 | 40.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 42 | 42 | $1,554 | $1,213 | 78.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 43 | 43 | $2,795 | $918.18 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 63 | $1,831 | $489.90 | 26.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 12 | 13 | $2,990 | $450.06 | 15.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 39 | 44 | $1,166 | $418.88 | 35.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 13 | $650.00 | $180.06 | 27.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 17 | 92 | $2,300 | $53.92 | 2.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 16 | 88 | $2,200 | $23.14 | 1.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 126 | 175 | $59,325 | $20,815 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 129 | 175 | $44,275 | $11,043 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 92 | $15,640 | $4,708 | 30.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 32 | 32 | $6,880 | $3,938 | 57.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 15 | 79 | $8,690 | $3,542 | 40.8% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 17 | 41 | $7,373 | $2,448 | 33.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 63 | 63 | $2,295 | $1,681 | 73.2% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 62 | 62 | $3,910 | $1,264 | 32.3% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 79 | 97 | $2,571 | $923.18 | 35.9% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 18 | 23 | $5,290 | $770.87 | 14.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 26 | 79 | $2,276 | $665.73 | 29.2% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 18 | 40 | $1,600 | $623.62 | 39.0% |
About Dr. Howard Mcmahan, MD
Dr. Howard Mcmahan, MD is a Family Medicine healthcare provider based in Ocilla, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1457473779.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Mcmahan, MD has received a total of $2,369 in payments from pharmaceutical and medical device companies, with $107.86 received in 2024. These payments were reported across 119 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,108).
As a Medicare-enrolled provider, Mcmahan has provided services to 3,334 Medicare beneficiaries, totaling 5,106 services with total Medicare billing of $198,620. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Ocilla, GA
- Active Since 04/06/2007
- Last Updated 03/13/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1457473779
Products in Payments
- Ozempic (Drug) $448.18
- Rybelsus (Drug) $250.88
- FARXIGA (Drug) $141.60
- TRELEGY ELLIPTA (Drug) $114.10
- JARDIANCE (Drug) $113.80
- XARELTO (Drug) $102.75
- MYRBETRIQ (Drug) $98.11
- SPIRIVA RESPIMAT (Drug) $96.21
- i-FACTOR Putty (Device) $94.16
- Myrbetriq (Drug) $84.83
- TRADJENTA (Drug) $79.55
- AREXVY (Drug) $67.26
- INVOKANA (Drug) $59.63
- BREZTRI (Drug) $49.69
- RYBELSUS (Drug) $45.34
- TRULICITY (Drug) $33.14
- GEMTESA (Drug) $22.80
- Aimovig (Biological) $21.13
- Kerendia (Drug) $20.52
- SYNJARDY (Drug) $19.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.